The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
So I hope to see some news out soon and it should flesh out details on a p3.
Does anyone have any thoughts on design and size?
I would think at will be at least three times of the data set so far, so upto 1000 patients. With a similar protocol as the p2. Multi centre, uk, us europe.
Do do so would require a partnership with a large pharma ( maybe) and run by a big third party.
Funding- some government funding wod be nice, but commercialized authorization would be nice.
Anyone else any thoughts.
Here are two articles of interest.
They may have already been posted.
https://www.bloomberg.com/news/articles/2020-09-24/covid-doctors-follow-dna-trail-to-potential-immune-treatment
https://www.theguardian.com/world/2020/sep/24/genetic-immune-defects-may-impair-ability-fight-covid-19
Nice sentiment.
I now rarely post here.
I've been a holder since early January. I've tried to ignore the SP and wait for news. Investors abhor the vacuum of no news. The drop in SP is disappointing however I suspect some of the flighty pi have bailed along with the likes of lansdowne.
To me things are progressing fine and at a pace so will wait for substantive news and act. In the mean time I have topped up another 5k share earlier this morning.
I'm holding for further news.
250k since January.
I bought for news on COPD, so I ignor the price and wait for results on that one way or another.
I only bought more when I'm in profit on my last purchase. I'll be driven by the news flow, if the next one is good and another RNS is expected I'll wait.
Hi and welcome-
You will tend to know if you are an insider - or you may be asked to come inside.
Your wife will have either an explicit rule that she can not buy stock or will be detailed in her employee handbook, but either way even if you work at Synairgen you may not be classed as an insider.
You may be in the lucky position of have more info or are just better informed..
I not sure if this had been previously posted here as its now hard to keep track of what goes on here.
I read this article which give a range of expert views on the SNG001 trial results. Whilst it is encouraging it does give a flavour of some of the hesitations which some experts may have following release of the trial results.
https://www.sciencemediacentre.org/expert-reaction-to-announcement-by-synairgen-that-their-drug-sng001-has-had-positive-results-in-initial-trials-on-covid-19-patients/
Morning Rich
Did you read this article
https://newatlas.com/health-wellbeing/heart-damage-recovered-covid19-patients-coronavirus/?itm_source=newatlas&itm_medium=most-viewed
Covid seem to damage the heart even if you weren't too I'll with it..
Here are a couple links to the dosing question and is cited in SNG001 paper
https://academic.oup.com/jid/article/doi/10.1093/infdis/jiaa350/5860074#205049044
It does not state it in the presentation but I shall check the webinar.
https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-data-readout-final-version.pdf
Ta LimaLima
SNG001 is very exciting but we must be objective. There will be 1000s of other treatments being worked up. Our drug is very exciting and should be part of the picture but other drugs will play their part.
Don't get get too carried away and look at the evidence objectively.